Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which exercise boosts heart efficiency best? new trial aims to find out

NCT ID NCT07485400

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will compare two types of aerobic exercise—interval training and continuous training—in 48 people with stable coronary artery disease. Participants will exercise twice a week for 8 weeks as part of a cardiac rehab program. Researchers will measure heart efficiency, exercise tolerance, blood pressure, and quality of life to see which approach works better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aerobic exercise training (interval or continuous)
What this could lead to
If successful, this could show that one type of aerobic exercise is better for improving heart efficiency and daily function in people with heart disease.
What could go wrong
This is a small, early-stage trial with only 48 participants, so results may not apply to everyone. The study is not yet recruiting, and the intervention is exercise, not a drug, so benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of cardiovascular disease requiring cardiac rehabilitation, with medical indication for a supervised exercise training program. * Prognostic risk classified as low or moderate according to the clinical risk stratification established in the unit, considering: * Killip class I or II (absence or mild heart failure)¹. * Absence of recent acute myocardial infarction (\< 1 month) or presence of a stable previous infarction. * Stable and well-controlled cardiovascular symptoms. * Physical capacity demonstrated in functional tests ≥ 5 METs, preferably \> 7 METs for low-risk patients. * Age between 40 and 75 years. * Ability to perform physical exercise without absolute contraindications. * Written informed consent and willingness to attend the scheduled sessions twice per week for 8 weeks. Exclusion Criteria: * High prognostic risk, defined by: * Killip class \> III (moderate to severe heart failure). * Recent acute myocardial infarction (\< 1 month) with clinical instability. * Active anginal symptoms or decompensated heart failure. * Physical capacity \< 5 METs on functional testing, indicating severely reduced exercise capacity. * Presence of complex or unstable arrhythmias contraindicating vigorous physical exercise. * Concomitant diseases that may limit participation or compromise safety (e.g., advanced pulmonary disease, severe renal failure, severe neuromuscular disorders). * Absolute medical contraindications to maximal strength or interval training (e.g., aortic aneurysm, uncontrolled hypertension). * Participation in another clinical trial or concurrent rehabilitation program. * Inability to comply with attendance requirements or to follow the intervention protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.